{"efta_number": "EFTA00287152", "page_count": 9, "url": "https://epstein-data.com/EFTA00287152", "pdf_url": "https://epstein-data.com/pdf/EFTA00287152.pdf", "pages": [{"efta_number": "EFTA00287152", "page_number": 0, "text_content": "09/14(2016 10:25:44 AM FROM:LABCORPLCLSFO \nTO: \nLABCORP \nTO: LISA P \nWoodson Merre \nPage 1 of 9 \nr \nL ?Agin,\nSpecamm Numb., \n252-436-4247-0 \nPut klotIO \nControl Mamba \n10416404914 \nAtoms Number \n31143092 \nAccount R\n Number \nRowe \nI 68 \nNbmc Um Nnw \nEpstein \nAnon Address \nWoodson Merrell \n44 E 67th St \nNew York NY \n10065 \nPaimaimNme \nJeffrey \nPuMwMADeNmx \nPadeaSP \nPricaMmac \n212-750-9895 \nTwalVokame \nar(Ymm) \n63/07/19 \nDared Binh \n01/20/53 \nSex \nM \nFladas \nYes \nPatna Address \n9 E 71ST ST \nNEW YORK \nNY \n10021 \nAdair/boil lobnintioo \nUPIN: A62553 \nnmeusinreColkaed \n09/08/16 08:23 \nDneEmmed \n09/08/16 \nDmearAlimeRepited \n09/13/16 15:06ET \nProichaName \nMERRELL \n, \nW \nNIM \nI \nPhysician ID \nLabCorp Raritan \n69 First Avenue \nRaritan. NJ 08869-1800 \n• \n- \n- \nTout Ordeal \nNKR LipoProfile; \nHeavy Metals Profile II, Blood; CBC With Differential/Platelet; \nComp. \nMetabolic Panel (14); IFE and PE, Serum; Urinalysis, \nRoutine; Lipid Panel; Iron and TIBC; \nTestosterone,Free+Weakly Bound; Ca+PTH Intact; \nVitamin B12 and Folate; Lyme Ab/Western Blot \nReflex; Hemoglobin Alc; Thyroxine (T4) Free, Direct, S; DHEA-Sulfate; Cortisol; \nTSH; Rheumatoid \nArthritis \nFactor; Prostate -Specific Ag, Serum; IGF-1; Vitamin D, 25-Hydroxy; Panel 083935; \nC-Reactive Protein, Cardiac; HCV Ab w/Rflx to Verification; ANA w/Reflex; Homocyst(e)ine, \nPlasma; Uric Acid, Serum; LDH; GGT; Magnesium, Serum; Zinc, Plasma or serum; Insulin; \nFerritin, \nSerum; Test Code Change; Venipuncture \nTESTS \nRESULT \nFLAG \nUNITS \nREFERENCE INTERVAL \nLAS \ntiHR LipoProfile \nLDL Particle \nNumber \nLDL-P \n1562 \nHigh \nnmol/L \nLow \nModerate \nBorderline -High \nHigh \nVery High \nLipids \nLDL-C \nTriglyceride \nresult \nindicated \nis \ncholesterol estimation. \ncomment: \nLDL-C is inaccurate \nHDL-C \nTriglycerides \nCholesterol, Total \nLDL and HDL Particles \nHDL-P (Total) \nSmall LDL-P \nLDL Size \n<1000 \n< 1000 \n1000 - 1299 \n1300 - 1599 \n1600 - 2000 \n> 2000 \nmg/dL \n0 \ntoo high for an accurate LDL \nOptimal \nAbove optimal \nBorderline \nHigh \nVery hi\n... [truncated, 2644 chars — for the full page use /api/corpus/document/EFTA00287152/0 or ?id=EFTA00287152&page=0]", "char_count": 2644}, {"efta_number": "EFTA00287152", "page_number": 1, "text_content": "09/1412016 10:25:44 AM FROM: LABCORP LCLS Fe \nTO: \nLAsconi,\nTO: LISA P \nWoodson Merrei ll \nPage 2 of 9 \nr \nLabCorp Raritan \n69 First Avenue \nRaritan, N1 0886 1800 \n: \n- \nPagan Nam \nEpstein, Jeffrey \nSpecimmigumber \n252-436-4247-0 \nAmmar Number \n31143092 \nPeeled ID \nControl Number \n10416404914 \nDate and Thee Collected \n09/08/16 08:23 \nD tieRepotted \n09/13/16 \nSa \nM \nAge(NANIM \n63/07/19 \nI/Annie& \n01/20/53 \nTESTS \nRESULT \nELAG \nUNITS \nREITOUNICE INTERVAL \nLAB \n** INTERPRETATIVE INFORMATION** \nPARTICLE CONCENTRATION AND SIZE \n<--Lower CVD Risk \nHigher CVD Risk--> \nLDL AND HDL PARTICLES \nPercentile in Reference Population \nHDL-P (total) \nHigh \n75th \n50th \n25th \nLow \n>34.9 \n34.9 \n30.5 \n26.7 \n<26.7 \nSmall LDL-P \nLow \n25th \n50th \n75th \nHigh \n<117 \n117 \n527 \n839 \n>839 \nLDL Size \n<-Large (Pattern A)-> \n<-Small (Pattern B)-> \n23.0 \n20.6 \n20.5 \n19.0 \nComment: \nSmall LDL-P and LDL Size are associated with CVD risk, but not after \nLDL-P is taken into account. \nThese assays were developed and their performance characteristics \ndetermined by LipoScience. These assays have not been cleared by the \nUS Food and Drug Administration. The clinical utility of these \nlaboratory values have not been fully established. \nInsulin Resistance Score \nLP-IR Score \n91 \nHigh \n<=45 \nINSULIN RESISTANCE MARKER \n<--Insulin Sensitive \nInsulin Resistant--> \nPercentile in Reference Population \ninsulin Resistance Score \nLP-IR Score \nLow \n25th \n50th \n75th \nHigh \n<27 \n27 \n45 \n63 \n>63 \nComment: \nLP-IR Score is inaccurate if patient is non-fasting. \nThe LP-IR score is a laboratory developed index that has been \nassociated with insulin resistance and diabetes risk and should be \nused as one component of a physician's clinical assessment. The \nLP-IR score listed above has not been cleared by the US Food and \nDrug Administration. \n01 \n01 \n01 \n01 \nHeavy Metals Profile II, Blood \nLead, Blood \nNone Detected \nug/dL \n0 - 19 \n01 \nEnvironmental Exposure: \nWHO Recommendation \n<20 \nOccupational Exposure: \nOSHA Lead Std \n4\n... [truncated, 2408 chars — for the full page use /api/corpus/document/EFTA00287152/1 or ?id=EFTA00287152&page=1]", "char_count": 2408}, {"efta_number": "EFTA00287152", "page_number": 2, "text_content": "09/14/2018 10:25:44 AM FROM:LABCORPLCUSF0 \nTO: \nLABCORP \nTO: LISA P \nWoodson Merrel l \nPage 3 of 9 \nr \nL.A.Csarp \nPatios Nave \nEpstein, Jeffrey \nSpodmen Number \n252-436-4247-0 \nAmami Number \n31143092 \nPMea ID \nCoal Number \n10416909919 \nDale ad Time Colluded \n09/08/16 08:23 \nDam Repotted \n09/13/16 \nSec \nM \nAge(YIM/D) \n63/07/19 \nDate of Beth \n01/20/53 \nTESTS \nRESULT \nFLAG \nUNITS \nREFERENCE INTERVAL \nLAS \nArsenic, Blood \n4 \nug/L \n2 - 23 \n01 \nDetection Limit = 1 \nMercury, Blood \n2.2 \nug/L \n0.0 - 14.9 \n01 \nEnvironmental Exposure: \n<15.0 \nOccupational Exposure: \nBEI - Inorganic Mercury: 15.0 \nDetection Limit = \n1.0 \nCadmium, Blood \nNone Detected \nug/L \n0.0 - 1.2 \n01 \nEnvironmental Exposure: \nNonsmokers \n0.3 - 1.2 \nSmokers \n0.6 - 3.9 \nOccupational Exposure: \nOSHA Cadmium Std \n5.0 \nBEI \n5.0 \nDetection Limit = 0.5 \nCBC With Differential/Platelet \nWBC \n5.8 \nx10E3/uL \n3.4 \n10.8 \n02 \nRBC \n4.95 \nx10E6/uL \n4.14 \n5.80 \n02 \nHemoglobin \n14.1 \ng/dL \n12.6 \n17.7 \n02 \nHematocrit \n41.9 \n8 \n37.5 \n51.0 \n02 \nMCV \n85 \nfL \n79 \n97 \n02 \nMCH \n28.5 \npg \n26.6 \n33.0 \n02 \nMCHC \n33.7 \n31.5 \n35.7 \n02 \nROW \n14.4 \n12.3 \n15.4 \n02 \nPlatelets \n232 \nxl0E3/uL \n150 \n379 \n02 \nNeutrophils \n51 \n8 \n02 \nLymphs \n32 \n8 \n02 \nMonocytes \n9 \n8 \n02 \nHos \n7 \n8 \n02 \nBasos \n1 \n8 \n02 \nNeutrophils (Absolute) \n3.0 \nx10E3/uL \n1.4 \n7.0 \n02 \nLymphs (Absolute) \n1.8 \nx10E3/uL \n0.7 \n3.1 \n02 \nMonocytes(Absolute) \n0.5 \nx10E3/uL \n0.1 \n0.9 \n02 \nEos (Absolute) \n0.4 \nx10E3/uL \n0.0 \n0.4 \n02 \nBaso (Absolute) \n0.0 \nxl0E3/uL \n0.0 \n0.2 \n02 \nImmature Granulocytes \n0 \n8 \n02 \nImmature Grans (Abs) \n0.0 \nx10E3/UL \n0.0 \n-\n \n0.1 \n02 \nComp. Metabolic Panel (14) \nGlucose, Serum \n96 \nmg/dL \n65 - 99 \n02 \nBUN \n16 \nmg/c1L \n8 - 27 \n02 \nCreatinine, Serum \n0.94 \nmg/dL \n0.76 - 1.27 \n02 \neGFR If NonAfricn Am \n86 \nmL/min/1.73 \n>59 \neGFR If Africn Am \n99 \nmL/min/1.73 \n>59 \nLabCorp Raritan \n69 First Avenue \nRaritan. NJ 08869-1800 \nPhone: 800-631-5250 \nEpstein, Jeffrey \n252-436-4247-0 \nSIN 48516 \n09/14/16 10:25 ET \nDUPLICATE FINAL REPORT \nThis dccwnent contains tit\n... [truncated, 2260 chars — for the full page use /api/corpus/document/EFTA00287152/2 or ?id=EFTA00287152&page=2]", "char_count": 2260}, {"efta_number": "EFTA00287152", "page_number": 3, "text_content": "09/141201610:25:444AM FROM:LABCORPLCLSFs \nTO: \nLABCORP \nTO: LISA P \nWoodson Merrell \nPage 4 of 9 \nr \nLalaggrap \npastoral= \nEpstein, Jeffrey \n4ralatomiabo \n252-436-4247-0 \nAccoaot Number \n31143092 \nNom ID \nCoon) Number \n10416404914 \nDate awl Time Collected \n09/08/16 08:23 \nDoe Repotted \n09/13/16 \nSex \nM \nAse(YrtND) \n63/07/19 \nDue of Bid, \n01/20/53 \nTESTS \nRESULT \nFLAG \nBUN/Creatinine Ratio \nSodium, Serum \nPotassium, Serum \nChloride, Serum \nCarbon Dioxide, Total \nCalcium, Serum \nProtein, Total, Serum \nAlbumin, Serum \nGlobulin, Total \nA/G Ratio \nBilirubin, Total \n17 \n139 \n4.4 \n99 \n22 \n9.5 \n6.7 \n4.3 \n2.4 \n1.8 \n0.8 \nAlkaline Phosphatase, S \n63 \nAST (SGOT) \n30 \nALT (SGPT) \n42 \nIFE and PE, Serum \nImmunoglobulin G, Qn, Serum \n1056 \nImmunoglobulin A, Qn, Serum \n224 \nImmunoglobulin M, Qn, Serum \n42 \nAlbumin \n3.6 \nAlpha-I-Globulin \n0.2 \nAlpha-2-Globulin \n0.8 \nBeta Globulin \n1.0 \nGamma Globulin \n1.0 \nM-Spike \nNot Observed \nGlobulin, Total \n3.1 \nA/G Ratio \n1.2 \nLibCorp Raritan \n69 First Avenue \nRaritan. NJ 08869-1800 \nPhone: 800-631-5250 \nUNITS \nstrounics INTERVAL \nmmol/L \nmmol/L \nmmol/L \nmmol/L \nmg/dL \ng/dL \ng/dL \ng/dL \nmg/dL \nIU/L \nIU/L \nIU/L \nmg/dL \nmg/dL \nmg/dL \ng/dL \ng/dL \ng/dL \ng/dL \ng/dL \ng/dL \ng/dL \nImmunofixation Result, Serum \nAn apparent normal immunofixation pattern. \nPlease note: \nProtein electrophoresis scan will follow via computer, \ncourier delivery. \nUrinalysis, Routine \nUrinalysis Gross Exam \nspecific Gravity \nPH \nUrine-Color \nAppearance \nWBC Esterase \nProtein \nGlucose \nKetones \nOccult Blood \nBilirubin \nUrobilinogen,Semi-Qn \nNitrite, Urine \n1.028 \n5.5 \nYellow \nClear \nNegative \nNegative \nNegative \nNegative \nTrace \nNegative \n0.2 \nNegative \nAbnormal \nEU/dL \n10 \n22 \n134 \n144 \n02 \n3.5 \n5.2 \n02 \n97 \n108 \n02 \n18 \n29 \n02 \n8.6 \n10.2 \n02 \n6.0 \n8.5 \n02 \n3.6 \n4.8 \n02 \n1.5 \n4.5 \n1.1 \n2.5 \n0.0 \n1.2 \n02 \n39 \n117 \n02 \n0 \n40 \n02 \n0 \n44 \n02 \n700 \n1600 \n02 \n61 \n437 \n02 \n20 \n172 \n02 \n2.9 \n4.4 \n02 \n0.0 \n0.4 \n02 \n0.4 \n1.0 \n02 \n0.7 \n1.3 \n02 \n0.4 \n1.8 \n02 \nNot Observed \n02 \n2.2 - 3.9 \n... [truncated, 2567 chars — for the full page use /api/corpus/document/EFTA00287152/3 or ?id=EFTA00287152&page=3]", "char_count": 2567}, {"efta_number": "EFTA00287152", "page_number": 4, "text_content": "09/14/2016 10:25:44 AM FROM:LABCORPLCLSF8 \nLABCORP \nTO: LISA P \nWoodson Merre \nPage 5 of 9 \nr \nLAkCosarP \nItadomName \nEpstein, Jeffrey \nSeecitheaNtotther \n252-436-4247-0 \nAccaux ?Iamb« \n31143092 \nPas ID \nCocoa Nuatee \n10416404914 \nDue end Thee Coleus \n09/08/16 08:23 \nDue Reported \n09/13/16 \nSec \nM \nAge(WAVD) \n63/07/19 \nDue of Bid. \n01/20/53 \nLabCorp Raritan \n69 First Avenue \nRaritan, NJ 08869-1800 \nPhone: 800- \n- \nTESTS \nRESULT \nFLAG \nUNITS \nREFERENCE INTERVAL \nLAS \nMicroscopic Examination \nWBC \nBBC \nEpithelial Cells (non renal) \nMucus Threads \nBacteria \nLipid Panel \nCholesterol, Total \nTriglycerides \nHDL Cholesterol \nComment \nSee below: \n0-5 \n0-2 \n/hpf \n/hpf \n0 - \n5 \n0 - \n2 \nNone seen \n/hpf \n0 - 10 \nPresent \nNot Estab. \nNone seen \nNone seen/Few \n214 \nHigh \nmg/dL \n100 - 199 \n470 \nHigh \nmg/dL \n0 - 149 \n27 \nLow \nmg/dL \n>39 \nAccording to ATP-III Guidelines, HDL-C >59 mg/dL \nnegative risk factor for CHD. \nVLDL Cholesterol Cal \nThe calculation for the VLDL cholesterol \ntriglyceride level is >400 mg/dL. \nLDL Cholesterol Calc \nTriglyceride result indicated is too high for \ncholesterol estimation. \nIron and TIBC \nIron Bind.Cap.(TIBC) \nUIBC \nIron, Serum \nIron Saturation \n302 \n219 \n83 \n27 \nTestosterone, Free+Weakly Bound \nTestosterone, Serum \n153 \nLow \nComment: \nAdult male reference interval is based on a population \nup to 40 years old. \nTestost., 9 Free+Weakly Bound \nTestost., F+W Bound \nCa+PTH Intact \nPTH, Intact \nIntact PTH \n31.6 \n48.3 \nng/dL \n40.0 - 250.0 \nis considered a \nmg/dL \nis not valid when \n5 - 40 \nmg/dL \n0 - 99 \nan accurate LDL \nug/dL \nug/dL \nug/dL \n250 - 450 \n111 - 343 \n38 - 169 \n15 - 55 \n02 \n02 \n02 \n02 \n02 \n02 \n02 \n02 \n02 \n02 \n02 \n02 \nng/dL \n348 - 1197 \n02 \nof lean males \n9.0 - 46.0 \n01 \n65 \nInterpretation \nNormal \nPrimary Hyperparathyroidism \nSecondary Hyperparathyroidism \nNon-Parathyroid Hypercalcemia \nHypoparathyroidism \npg/mL \nIntact PTH \n(pg/mL) \n15 - 65 \n>65 \n>65 \n<65 \n<15 \n15 - 65 \n02 \n02 \nCalcium \n(mg/dL) \n8.6 - 10.2 \n>10.2 \n<10.2 \n>10.2 \n< 8.6 \nEpstein\n... [truncated, 2364 chars — for the full page use /api/corpus/document/EFTA00287152/4 or ?id=EFTA00287152&page=4]", "char_count": 2364}, {"efta_number": "EFTA00287152", "page_number": 5, "text_content": "09114/201610:25:44AM FROM:LABCORPLCISF6 \nTO: \nLABCORP \nTO: LISA P \nWoodson Merrell \nPage 6 of 9 \nr \nLabgrap \nibthaNum \nEpstein, Jeffrey \nSpecharmNurber \n252-436-4247-0 \nAna Sao \n31143092 \nNem M \nComet Nat \n10416404914 \nDee aornme Conected \n09/08/16 08:23 \nDate Mowed \n09/13/16 \nSc \nM \nAge(Y/M0) \n63/07/19 \nDate of Birth \n01/20/53 \nTESTS \nRESULT \nFLAG \nUNITS \nREFERENCE INTERVAL \nLAB \nNon-Parathyroid Hypocalcemia \nVitamin B12 and Folate \n15 - 65 \n< 8.6 \nVitamin 812 \n945 \npg/mL \n211 - 946 \n02 \nFolate (Folic Acid), Serum \n9.9 \nng/m1, \n>3.0 \n02 \nNote: \n02 \nA serum folate concentration of less than 3. \nconsidered to represent clinical deficiency. \n1 ng/mL is \nLyme Ab/Western Blot Reflex \nLyme IgG/IgM Ab \n<0.91 \nISR \n0.00 - 0.90 \n02 \nNegative \n<0.91 \nEquivocal 0.91 - 1.09 \nPositive \n>1.09 \nLyme Disease Ab, Quant, IgM \n<0.80 \nindex \n0.00 - 0.79 \n02 \nNegative \n<0.80 \nEquivocal 0.80 - 1.19 \nPositive \n>1.19 \nIgM levels may peak at 3-6 weeks post infection, then \ngradually decline. \nHemoglobin Aic \nHemoglobin Aic \n5.8 \nHigh \n4.8 - 5.6 \nPlease Note: \n02 \n02 \nPre-diabetes: 5.7 - 6.4 \nDiabetes: >6.4 \nGlycemic control for adults with diabetes: <7.0 \nThyroxine (T4) Free, Direct, S \nT4,Pree(Direct) \n1.13 \nng/dL \n0.82 - 1.77 \n02 \nDBEA-Sulfate \n155.3 \nug/dL \n48.9 - 344.2 \n02 \ncortisol \n14.1 \nug/dL \n02 \nCortisol AM \n6.2 - 19.4 \nCortisol PH \n2.3 - 11.9 \nTSB \n1.800 \nuIU/mL \n0.450 - 4.500 \n02 \nRheumatoid Arthritis rector \nRA Latex Turbid. \n5.8 \nIUML \n0.0 - 13.9 \n02 \nLabCorp Raritan \n69 First Avenue \nRaritan NJ 08869-1800 \nPhone: 800-631-5250 \nEpstein, Jeffrey \n09/14/16 10:25 ET \nDUPLICATE FINAL REPORT \nThis document cornaim private and confidential health information protected by slate and federal law. \nIf you have received this document m error, please call 800-631-5250 \n252-436-4247-0 \nSeq I 8516 \nPage 6 of 8 \n02001-16 Laboratory Corporation d America m Holdings \nAU Rights Reserved \nDOC I Ver: 149 \nEFTA00287157\n", "char_count": 1921}, {"efta_number": "EFTA00287152", "page_number": 6, "text_content": "09114/201610:25:44AM FROM:LABCORPLCUSFe \nLABCORP \nTO: LISA P \nWoodson Me \nPage 7 of 9 \nr \nLQ,bQcarwp \nPatient Name \nEpstein, Jeffrey \nSpedmeo Number \n252-436-4247-0 \nAccount Number \n31143092 \nNorm ID \nCoaxed Number \n10416404914 \nDam sod Time Collected \n09/08/16 08:23 \nDae Rmoned \n09/13/16 \nSt= \nM \nArea/WD) \n63/07/19 \nDate of Bit) \n01/20/53 \nLabCorp Raritan \n69 First Avenue \nRaritan NJ 08869-1800 \nPhone: 800-631-5250 \nTESTS \nRESULT \nFLAG \nUNITS \nREFERENCE INTERVAL \nLAB \nProstate-Specific Ag, Serum \nProstate Specific Ag, Serum \nRoche ECLIA methodology. \n0.6 \nng/mL \n0.0 - 4.0 \nAccording to the American Urological Association, Serum PSA should \ndecrease and remain at undetectable levels after radical \nprostatectomy. The AUA defines biochemical recurrence as an initial \nPSA value 0.2 ng/mL or greater followed by a subsequent confirmatory \nPSA value 0.2 ng/mL or greater. \nValues obtained with different assay methods or kits cannot be used \ninterchangeably. Results cannot be interpreted as absolute evidence \nof the presence or absence of malignant disease. \nIGF-1 \nInsulin-Like Growth Factor I \n151 \nng/ra. \n02 \n49 - 188 \n01 \nVitamin D, 25-Hydroxy \n34.0 \nng/mL \n30.0 - 100.0 \n02 \nVitamin D deficiency has been defined by the Institute of \nMedicine and an Endocrine Society practice guideline as a \nlevel of serum 25-OH vitamin D less than 20 ng/mL (1,2). \nThe Endocrine Society went on to further define vitamin D \ninsufficiency as a level between 21 and 29 ng/mL (2). \n1. IOM (Institute of Medicine). 2010. Dietary reference \nintakes for calcium and D. Washington DC: The \nNational Academies Press. \n2. Holick MF, Hinkley NC, Bischoff-Ferrari HA, et al. \nEvaluation, treatment, and prevention of vitamin D \ndeficiency: an Endocrine society clinical practice \nguideline. JCEM. 2011 Jul; 96(7):1911-30. \nPanel 083935 \nHIV Screen 4th Generation wRfx \nNon Reactive \nNon Reactive \n02 \nC-Reactive Protein, Cardiac \nHCV Ab w/Rflx to Verification \nHCV Ab \nComment: \nNon reactive HCV antibody screen\n... [truncated, 2678 chars — for the full page use /api/corpus/document/EFTA00287152/6 or ?id=EFTA00287152&page=6]", "char_count": 2678}, {"efta_number": "EFTA00287152", "page_number": 7, "text_content": "09/14/2016 10:25:44 AM FROM: LABCORP LCLS F6 \nT \nLABCORP \nTO: LISA P \nWoodson M \nPegs 8 of 9 \nr \nL&Qcsp \nDeiccoName \nEpstein, Jeffrey \nSpecimen Hunter \n252-436-4247-0 \nMooing Hinter \n31143092 \nPoirot M \nOman) Nuts \n10416404914 \nDow and Thus °Awed \n09/08/16 08:23 \nDas Reporeed \n09/13/16 \nSot \nM \nAse0(440 \n63/07/19 \nDate of Birds \n01/20/53 \nLabCorp Raritan \n69 First Avenue \nRaritan NJ 08869-1800 \nPhes6:800 -631 -5250 \nTESTS \nANA w/Reflex \nANA Direct \nRomocyst(e)ine, Plasma \nUric Acid, Serum \nUric Acid, Serum \nPlease Note: \nLDH \nGGT \nMagnesium, Serum \nZinc, Plasma or Serum \nInsulin \nFerritin, Serum \nTest Code Change \nRESULT \nFLAG \nUNITS \nREFERENCE INTERVAL \nLAB \nNegative \nNegative \n02 \n16.0 \nHigh \numol/L \n0.0 - 15.0 \n02 \n7.1 \nmg/dL \n3.7 - 8.6 \n02 \n02 \nTherapeutic target for gout patients: <6.0 \n171 \nIU/L \n121 - 224 \n02 \n24 \nIU/L \n0 \n65 \n02 \n2.0 \nmg/dL \n1.6 - 2.3 \n02 \n89 \nug/dL \n56 - 134 \n01 \nDetection Limit = 5 \n11.1 \nuIU/mL \n2.6 - 24.9 \n02 \n98 \nng/mL \n30 - 400 \n02 \n02 \n**Effective May 8, 2016, HIV-1/0/2 Antibodies, Preliminary Test with** \nConfirmation (Third Generation) has been discontinued. \nPlease note the HIV-1/0/2 Antibodies, Preliminary Test with \nConfirmation was updated to HIV-1/0/2 Antigen/Antibody (Fourth \nGeneration) Preliminary Test with cascade reflex to Supplementary \nTesting by LabCorp. For future orders, please use the HIV-1/O/2 \nAntigen/Antibody test number 083935. Contact your LabCorp Key Account \nExecutive to request new custom profile(s) containing 083935. \n01 \nBN \nLabCorp Burlington \n1447 York Court, Burlington, \n02 \nRN \nLabCorp Raritan \n69 First Avenue, Raritan, NJ \nFor inquiries, the physician nay contact \nDir: William F Hancock, ND \nNC 27215-3361 \nDir: Araceli B Reyes, ND \n08869-1800 \nBranch: 800-631-5250 Lab: 800-631-5250 \nEpstein, Jeffrey \n09/14/16 10:25 ET \nDUPLICATE FINAL REPORT \nThis document canal= pint and confldentid health infonnatioo protected by state and federal law. \nif you have received this document in trite. please call 800-631\n... [truncated, 2152 chars — for the full page use /api/corpus/document/EFTA00287152/7 or ?id=EFTA00287152&page=7]", "char_count": 2152}, {"efta_number": "EFTA00287152", "page_number": 8, "text_content": "Lata Mil\nitia ST \nWoodson Merre \nSpecial Chemistry Department \nRaritan New Jersey \nSerum Immunofixation and Electrophoresis \nraga 9 or \nSerum Proteins IFE Gel T44385 Sample 45 09/09/2016 13:51:29:44 \n252436424709 \nAccession Number \n252436424709 \nPhysician ID \nMERRELL W \nPatient Name \nEpstein, Jeffrey \nAccount Address 1 \nTotal Protein \n6.7 \nAccount Address 2 \n44 E 67th St \nPatient ID \nAccount Address 3 \nNew York, NY 10065 \nBirthdate \n1/20/1953 \nAccount No./Name \n31143092-Woodson Merrell \nFraction \n% \ng/dl \ng/dl Range \nAlbumin \n53.9 \n3.6 \n3.2 to \n5.6 \nAlpha-1 \n3.0 \n0.2 \n0.1 to \n0.4 \nAlpha-2 \n12.6 \n0.8 \n0.4 to \n1.2 \nBeta \n15.4 \n1.0 \n0.6 to \n1.3 \nGamma \n15.0 \n1.0 \n0.5 to \n1.6 \nTotal \n6.7 \n6.0 to \n8.5 \nComments \nAn apparent normal immundIxatIon pattern. \nEFTA00287160\n", "char_count": 773}]}